| __timestamp | Dr. Reddy's Laboratories Limited | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 56369000000 | 14400000 |
| Thursday, January 1, 2015 | 62786000000 | 33800000 |
| Friday, January 1, 2016 | 62427000000 | 35900000 |
| Sunday, January 1, 2017 | 62453000000 | 1254000 |
| Monday, January 1, 2018 | 65724000000 | 4889000 |
| Tuesday, January 1, 2019 | 70421000000 | 7400000 |
| Wednesday, January 1, 2020 | 80591000000 | 10100000 |
| Friday, January 1, 2021 | 86645000000 | 14300000 |
| Saturday, January 1, 2022 | 100551000000 | 23200000 |
| Sunday, January 1, 2023 | 42907000000 | 39700000 |
| Monday, January 1, 2024 | 115557000000 | 34000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. Dr. Reddy's Laboratories Limited and Neurocrine Biosciences, Inc. offer a fascinating study in contrasts. Over the past decade, Dr. Reddy's Laboratories has consistently maintained a robust cost of revenue, peaking at approximately 115% of its 2014 value by 2024. This reflects a steady growth trajectory, underscoring its expansive market reach and operational scale.
Conversely, Neurocrine Biosciences, Inc. presents a more volatile picture. Starting with a modest cost of revenue in 2014, it experienced a dramatic surge, reaching nearly 275% of its initial value by 2023. This fluctuation highlights the dynamic nature of smaller biotech firms navigating innovation and market challenges.
While Dr. Reddy's Laboratories showcases stability, Neurocrine's journey is a testament to the high-stakes world of biotech innovation, where costs can be as unpredictable as the breakthroughs themselves.
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Cost Insights: Breaking Down United Therapeutics Corporation and Dr. Reddy's Laboratories Limited's Expenses
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Cost of Revenue Trends: Incyte Corporation vs Dr. Reddy's Laboratories Limited
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Jazz Pharmaceuticals plc
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs MorphoSys AG
Dr. Reddy's Laboratories Limited vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Celldex Therapeutics, Inc.